What is the recommended dosing regimen for olanzapine (Zyprexa) for adult schizophrenia and bipolar disorder, including adjustments for elderly patients and those with hepatic impairment?

Zyprexa (Olanzapine) Dosing

For adult schizophrenia, start with 5-10 mg once daily (target 10 mg/day), with a maximum of 20 mg/day; for bipolar disorder, start with 10-15 mg once daily (range 5-20 mg/day); elderly patients and those with hepatic impairment should start at 5 mg daily with cautious titration. 1

Adult Schizophrenia Dosing

Initial and Target Dosing:

• Starting dose: 5-10 mg once daily, generally targeting 10 mg/day within several days 1
• Target dose: 10 mg/day is the evidence-based target, as doses above 10 mg/day were not demonstrated to be more efficacious in clinical trials 1
• Dose adjustments: If needed, increase in 5 mg increments at intervals of ≥1 week (reflecting time to steady state) 1
• Maximum dose: 20 mg/day; olanzapine is not indicated above this dose 1
• Therapeutic range: Efficacy demonstrated in 10-15 mg/day range 1

Key principle: Doses above 10 mg/day should only be used after clinical assessment shows inadequate response, not as routine practice 1

Adult Bipolar I Disorder Dosing

Acute Mania (Monotherapy):

• Starting dose: 10-15 mg once daily 1
• Dose adjustments: 5 mg increments at intervals ≥24 hours 1
• Therapeutic range: 5-20 mg/day (demonstrated efficacy range) 1
• Maximum: 20 mg/day 1

Adjunctive Treatment (with lithium or valproate):

• Starting dose: 10 mg once daily 1
• Range: 5-20 mg/day 1

Special Populations

Elderly Patients

Critical dosing modifications are required:

• Starting dose: 5 mg daily (reduced from standard 10 mg) 1
• Rationale: Elderly patients, particularly nonsmoking females ≥65 years, have slower olanzapine metabolism and increased pharmacodynamic sensitivity 1
• Titration: Perform dose escalation with caution 1
• Supporting evidence: Studies in elderly patients with psychotic disorders used 5-20 mg/day range, with careful monitoring for orthostatic hypotension, sedation, and extrapyramidal symptoms 2, 3

Hepatic Impairment

Dose reduction is mandatory:

• Starting dose: 5 mg daily 1
• Monitoring: Recent real-world data shows 24.2% incidence of hepatotoxicity in bipolar patients, predominantly mild (19.3%) 4
• Risk factors: Higher daily doses (OR 1.070 per mg increase) and elevated baseline GGT independently predict hepatotoxicity 4
• Clinical implication: Use lowest effective dose and monitor liver function regularly, especially in first months of treatment 4

Debilitated Patients or Those Predisposed to Hypotension

• Starting dose: 5 mg daily 1
• Considerations: This includes patients with multiple risk factors for slower metabolism 1

Adolescent Dosing (Ages 13-17)

Schizophrenia:

• Starting dose: 2.5-5 mg once daily 1
• Target dose: 10 mg/day 1
• Studied range: 2.5-20 mg/day (mean modal dose 12.5 mg/day in trials) 1
• Dose adjustments: 2.5-5 mg increments 1
• Maximum: 20 mg/day (higher doses not evaluated) 1

Bipolar I Disorder (Manic/Mixed):

• Starting dose: 2.5-5 mg once daily 1
• Target dose: 10 mg/day 1
• Studied range: 2.5-20 mg/day (mean modal dose 10.7 mg/day in trials) 1
• Dose adjustments: 2.5-5 mg increments 1

Important caveat: Adolescents experience more pronounced metabolic adverse effects (weight gain, dyslipidemia, glycemic abnormalities) than adults, making olanzapine best positioned as second-line in youth 5

Alternative Dosing Contexts

Early Psychosis (First Episode):

• Initial target: 7.5-10 mg/day 6
• Rationale: Lower doses appropriate for first-episode patients to minimize extrapyramidal side effects and encourage adherence 6
• Maximum: Generally 10 mg/day in this population 6

Delirium Management (Off-label):

• Starting dose: 2.5-5 mg PO/SC stat 7
• Scheduled dosing: 2.5-5 mg daily (usually at bedtime) if regular dosing required 7
• Special considerations: Reduce dose in elderly and hepatic impairment; avoid combining with benzodiazepines due to risk of oversedation and respiratory depression 7

Breakthrough Chemotherapy-Induced Nausea/Vomiting:

• Dose: 5-10 mg PO daily (Category 1 recommendation) 8

Administration Considerations

• Timing: Once daily, without regard to meals 1
• Formulations: Available as standard tablets, orally disintegrating tablets (ZYDIS), and intramuscular injection 1
• ZYDIS administration: Place entire tablet in mouth using dry hands; disintegrates rapidly and can be swallowed with or without liquid 1

Maintenance Treatment

Schizophrenia:

• Maintenance range: 10-20 mg/day demonstrated effective in preventing relapse 1
• Duration: Continue at lowest effective dose; periodically reassess need for ongoing treatment 1

Bipolar I Disorder:

• Maintenance range: 5-20 mg/day after achieving response 1
• Strategy: Continue beyond acute response at lowest dose maintaining remission 1

Critical Safety Monitoring

Metabolic monitoring is essential:

• Weight gain is dose-related and occurs commonly 9
• Monitor liver function regularly, especially in first months and with higher doses 4
• Baseline and periodic assessment of glucose, lipids, and weight 4
• Concomitant valproate may reduce hepatotoxicity risk (OR 0.553) 4

Drug interactions:

• Smoking status affects metabolism (nonsmokers have higher exposure) 1
• Quetiapine co-administration significantly reduces olanzapine clearance (ratio 0.152:1), requiring dose adjustment 10

Practical Dosing Algorithm

1. Determine patient category: Adult vs. adolescent vs. elderly vs. hepatic impairment
2. Select starting dose:
   • Standard adult: 5-10 mg
   • Elderly/hepatic impairment/debilitated: 5 mg
   • Adolescent: 2.5-5 mg
3. Target appropriate dose:
   • Schizophrenia: 10 mg/day
   • Bipolar mania: 10-15 mg/day
4. Titrate cautiously: Wait ≥1 week between adjustments (≥24 hours for acute mania)
5. Reassess before exceeding 10 mg/day: Only increase if clinically indicated after thorough assessment
6. Never exceed 20 mg/day
7. Monitor metabolic parameters and liver function throughout treatment